Population
Patients with nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH)
Design
Review
Authors
Loading...
Highlights unmet need for NASH pharmacotherapies; leaves open discovery of effective, well-tolerated agents targeting pathophysiology.
This review highlights the growing burden of NASH and the unmet need for effective, well-tolerated pharmacological therapies targeting its underlying pathophysiology.
Schattenberg et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: